Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05924841 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 100 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06726148 | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Novartis PharmaceuticalsINDUSTRY | 16 | Aug 27, 2026 |
| clinicaltrials |
| NCT06822543 | A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)(TROPICAL-1) | recruiting | Phase 2 | 46 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07158489 | Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC(ORIGIN2) | recruiting | Phase 2 | 47 | Swiss Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer(RAINFOL-05) | recruiting | Phase 2 | 240 | GenmabINDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT07718672 | Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | recruiting | Phase 1 / Phase 2 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 25, 2026 | clinicaltrials |
| NCT05948813 | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | recruiting | Phase 2 | 420 | TYK Medicines, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | recruiting | Phase 2 | 96 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT07250477 | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 56 | University of California, DavisOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07412262 | A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression(NSCLC， YAP) | recruiting | Phase 2 | 32 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05987826 | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT04933903 | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | recruiting | Phase 2 | 25 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07133425 | A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07329322 | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07017829 | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774520 | A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy | recruiting | Phase 2 | 1,173 | Samsung Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06514027 | Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations | recruiting | Phase 2 | 30 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06731907 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | recruiting | Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer(ALISCA-Lung1) | recruiting | Phase 2 | 120 | Puma Biotechnology, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06616766 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | recruiting | Phase 1 / Phase 2 | 201 | Yuhan CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06768307 | Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06120803 | Esomeprazole and Radiation Induced Esophagitis(EERENs) | recruiting | Phase 2 | 48 | Rush University Medical CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06518057 | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer | recruiting | Phase 2 | 22 | University of WashingtonOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06878274 | Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC(RESCUE) | recruiting | Phase 2 | 118 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05276726 | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | recruiting | Phase 1 / Phase 2 | 104 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 240 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT04199741 | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | recruiting | Phase 1 / Phase 2 | 105 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07697586 | SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer | recruiting | Phase 2 | 206 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759856 | NK Cells Plus ICI for SCLC Maintenance(NK-ICI-SCLC) | recruiting | Phase 2 | 42 | Tianjin First Central HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06656598 | Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer(SPORADIC) | recruiting | Phase 2 | 152 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06222489 | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT | recruiting | Phase 2 | 16 | The Netherlands Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT07590531 | AMT-116 in Combination With AK112 in Patients With Lung Cancer | recruiting | Phase 1 / Phase 2 | 118 | Multitude Therapeutics Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical（Suzhou）Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06634056 | Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation(P4-PACIFIC) | recruiting | Phase 2 | 150 | University Health Network, TorontoOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06449313 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features(NEO-SURG) | recruiting | Phase 2 | 21 | Georgetown UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2026source: clinicaltrials